Zacks.com on MSN3h
Regeneron to Report Q4 Earnings: Is a Beat in the Cards?
Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report fourth-quarter and full-year 2024 results on Feb. 4, 2025. The Zacks Consensus Estimate for fourth-quarter revenues is pegged at ...
FiercePharma6h
Eylea-Vabysmo battle wages on as UK marketing watchdog reaffirms Bayer’s claims of ‘misleading’ Roche promos
The fight for dominance between Regeneron and Bayer’s big blockbuster eye drug Eylea and Roche’s rival Vabysmo is playing out ...
Webster County Citizen3d
Debate over Roundup bill focuses on herbicide's safety
Roundup's label has a pesticide warning approved by the U.S. Environmental Protection Agency. The bill declares the existing label "sufficient to satisfy any requirement for a warning label regarding ...
As Missouri Republicans race to shield Bayer from lawsuits, bills face bipartisan opposition
An avalanche of lawsuits filed against Bayer in Missouri is pitting the chemical maker against trial attorneys and cancer patients.